New Hope for Mobilization Failures . . . Again

References 

1. Schroeder MA, DiPersio JF. Mobilization of hematopoietic stem and leukemia cells. J Leuk Biol. 2012;91:1–11
2. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and hematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466:829–836
   • CrossRef
3. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14:1045–1056
   • Abstract
   • Full Text
   • Full-Text PDF (1410 KB)
   • CrossRef
4. Attolica I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant. 2011;18:241–249
   • Abstract
   • Full Text
   • Full-Text PDF (155 KB)
   • CrossRef
5. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41:331–338
   • CrossRef
6. Kubel K, Fresen M, Apperley J, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant. 2011 Nov 14;[Epub ahead of print]